Articles by Lauren Evoy Davis
AMPLIFY trial shows AVO combo achieves deep remissions in CLL patients with high-risk TP53 aberrations.
10-year RESONATE-2 results show ibrutinib delivers lasting survival benefits for CLL/SLL as first-line therapy.
Cardiovascular complications, such as those associated with arterial or venous thromboembolism, are a prominent concern.
Liso-cel outperforms standard care in second-line LBCL, showing 29.5-month EFS vs 2.4 months in TRANSFORM trial.
Infections affect 25% of LBCL patients post-CD19 CAR T-cell therapy, with risks linked to age, CRS, and poor performance.
AMPLIFY trial shows acalabrutinib with venetoclax and obinutuzumab significantly improves PFS over chemoimmunotherapy in CLL.
Zanubrutinib shows PFS benefit over BR in high-risk CLL/SLL patients, per 5-year SEQUOIA trial data.
630 Madison Ave.
Manalapan, NJ 07726
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.